Artificial Cell Engineering Technology Research Center of Public Health Ministry, Tianjin Key Laboratory of Artificial Cells, Tianjin Institute for Hepatobiliary Disease, Tianjin Third Central Hospital, Tianjin, China.
Department of Hepatobiliary Surgery, Tianjin Third Central Hospital, Tianjin, China.
J Histochem Cytochem. 2019 May;67(5):299-308. doi: 10.1369/0022155418824274. Epub 2019 Jan 11.
Chemokines and their receptors have been proposed to play important roles in tumor progression and metastasis. To investigate their roles in the progression of primary and metastatic malignant liver tumors and their prognosis, we compared expression profiles of CXCL12/CXCR4, CCL20/CCR6, and CCL21/CCR7 in hepatocellular carcinoma (HCC) and colorectal liver metastases (CRLM). Immunohistochemistry was used to analyze the expression levels of the chemokine/chemokine receptor pairs in 29 HCC and 11 CRLM specimens and adjacent non-cancerous tissues, and correlations with clinicopathological variables and overall survival were determined. CCL20/CCR6 expression was higher in HCC than in adjacent non-cancerous tissues. High CCR6 expression in HCC was negatively associated with 5-year survival rate and was an independent prognostic factor for overall survival of HCC patients, whereas differences were not observed between CRLM and adjacent tissues. Furthermore, significantly higher expression of CCL21/CCR7 was found in CRLM than in HCC. In summary, the CCL20/CCR6 axis was elevated in HCC but not in CRLM, whereas the CCL21/CCR7 axis was elevated in CRLM but not in HCC.
趋化因子及其受体被认为在肿瘤的进展和转移中发挥重要作用。为了研究它们在原发性和转移性恶性肝肿瘤的进展及其预后中的作用，我们比较了趋化因子 CXCL12/CXCR4、CCL20/CCR6 和 CCL21/CCR7 在肝细胞癌 (HCC) 和结直肠癌肝转移 (CRLM) 中的表达谱。免疫组织化学用于分析 29 例 HCC 和 11 例 CRLM 标本及其相邻非癌组织中趋化因子/趋化因子受体对的表达水平，并确定与临床病理变量和总生存率的相关性。CCL20/CCR6 在 HCC 中的表达高于相邻非癌组织。HCC 中 CCR6 的高表达与 5 年生存率呈负相关，并且是 HCC 患者总生存率的独立预后因素，而在 CRLM 与相邻组织之间未观察到差异。此外，在 CRLM 中发现 CCL21/CCR7 的表达显著高于 HCC。总之，CCL20/CCR6 轴在 HCC 中升高而在 CRLM 中不升高，而 CCL21/CCR7 轴在 CRLM 中升高而在 HCC 中不升高。
